Last updated: 2026-10-19 04:33:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
BridgeBio Oncology Therapeutics, Inc. (BBOT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.83, with a market capitalization of $226.09M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.81 to $14.87. This page covers its latest market performance, valuation, price trends and company information.
$226.09M | |
$2.95 | |
$14.87 | |
$2.81 | |
$2.95 | |
422.60K | |
476.66K | |
-- | |
$14.87 | |
$2.81 | |
-- | |
-- |
BridgeBio Oncology Therapeutics, Inc. (BBOT) last closed at $2.95 as of 2026-10-16 23:31:00, unchanged from the previous close of $2.95.
During the latest regular trading session, BBOT traded between $2.81 and $14.87, with a volume of 422.60K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, BridgeBio Oncology Therapeutics, Inc. (BBOT) moved from $3.42 to $2.83, representing a decline of 17.40% ($0.59).
The stock traded between $2.81 and $3.50 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 453.30 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.1%
BBOT is currently trading at $2.83, placing it 0.1% of the way from its 52-week low of $2.81 to its 52-week high of $14.87. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 88 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.